stoxline Quote Chart Rank Option Currency Glossary
Nabriva Therapeutics plc (NBRV)
1.42  0.01 (0.71%)    07-31 16:00
Open: 1.45
High: 1.9
Volume: 706,536
Pre. Close: 1.41
Low: 1.35
Market Cap: 5(M)
Technical analysis
2023-10-20 4:25:16 PM
Short term     
Mid term     
Targets 6-month :  0.82 1-year :  1.03
Resists First :  0.7 Second :  0.88
Pivot price 0.54
Supports First :  0.4 Second :  0.34
MAs MA(5) :  0.46 MA(20) :  0.58
MA(100) :  1.23 MA(250) :  1.63
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  8 D(3) :  14
RSI RSI(14): 34.9
52-week High :  2.86 Low :  0.37
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NBRV ] has closed above bottom band by 16.1%. Bollinger Bands are 7.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.55 - 0.55 0.55 - 0.56
Low: 0.4 - 0.41 0.41 - 0.41
Close: 0.41 - 0.41 0.41 - 0.41
Company Description

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Headline News

Tue, 01 Aug 2023
Nabriva Therapeutics (OTCPK:NBRV.F) - Stock Price, News & Analysis - Simply Wall St

Mon, 06 Feb 2023
NBRV stock on watch as Merck ends distribution agreement (NASDAQ:NBRV) - Seeking Alpha

Fri, 06 Jan 2023
Nabriva Therapeutics Provides Corporate Update - Yahoo Finance

Thu, 15 Sep 2022
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split - GlobeNewswire

Mon, 18 Jul 2022
Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals - GlobeNewswire

Thu, 16 Jul 2020
Nabriva Soars on Agreement With Merck to Distribute Sivextro - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -3.2
Sales Per Share 11.4
EBITDA (p.s.) -14.65
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0.03
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android